Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373664" target="_blank" >RIV/00216208:11130/17:10373664 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/17:10373664

Výsledek na webu

<a href="https://doi.org/10.2217/fon-2017-0189" target="_blank" >https://doi.org/10.2217/fon-2017-0189</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/fon-2017-0189" target="_blank" >10.2217/fon-2017-0189</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study

Popis výsledku v původním jazyce

Aim: To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC). Patients &amp; methods: Patients were randomly assigned to 10, 20 mu g/kg palonosetron or 3 x 150 mu g/kg ondansetron for up to four cycles of HEC/MEC. Results: In all on-study chemotherapy cycles, complete response rates were higher in patients in the 20 mu g/kg palonosetron group than the ondansetron group. Treatment-emergent adverse events were comparable between the palonosetron 20 mu g/kg and ondansetron groups. Conclusion: Over four cycles of HEC/MEC, 20 mu g/kg palonosetron was an efficacious and safe treatment for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.

Název v anglickém jazyce

Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study

Popis výsledku anglicky

Aim: To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC). Patients &amp; methods: Patients were randomly assigned to 10, 20 mu g/kg palonosetron or 3 x 150 mu g/kg ondansetron for up to four cycles of HEC/MEC. Results: In all on-study chemotherapy cycles, complete response rates were higher in patients in the 20 mu g/kg palonosetron group than the ondansetron group. Treatment-emergent adverse events were comparable between the palonosetron 20 mu g/kg and ondansetron groups. Conclusion: Over four cycles of HEC/MEC, 20 mu g/kg palonosetron was an efficacious and safe treatment for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Future Oncology

ISSN

1479-6694

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

19

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

14

Strana od-do

1685-1698

Kód UT WoS článku

000409493600005

EID výsledku v databázi Scopus

2-s2.0-85028573236